TRxADE HEALTH Reports Year End 2021 Financial Results
TRxADE HEALTH (NASDAQ:MEDS) announced its Q4 2021 and FY 2021 financial results, highlighting a 19.7% revenue increase to $2.4 million in Q4, attributed to the TRxADE Platform. Gross profit surged 831% to $1.24 million, reflecting improved cost efficiency. However, FY 2021 revenues dropped 42.2% to $9.9 million, largely due to decreased PPE sales in 2021. The net loss for Q4 was ($0.8) million, improving from ($2.3) million year-over-year. Cash reserves decreased to $3.1 million, attributed to IT initiatives and inventory losses.
- Q4 2021 revenue increased 19.7% to $2.4 million.
- Gross profit in Q4 2021 increased 831% to $1.24 million.
- Operating expenses reduced to $2.0 million in Q4 2021 from $2.4 million.
- FY 2021 revenue decreased 42.2% to $9.9 million.
- Net loss for FY 2021 was ($5.3) million, worsening from ($2.5) million in the previous year.
- Adjusted EBITDA for FY 2021 was negative ($3.7) million compared to positive $0.1 million in FY 2020.
Continues Nationwide Expansion of Breakthrough Digital Healthcare Services IT Platform
TAMPA, FL / ACCESSWIRE / March 28, 2022 / TRxADE HEALTH, INC. (NASDAQ:MEDS)("TRxADE", "TRxADE HEALTH" or the "Company"), a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., today announced its financial results for the fourth quarter (Q4) and year ended (FY) December 31, 2021.
Fourth Quarter 2021 Financial Summary and Operational Highlights
TRxADE continued to expand the TRxADE drug procurement marketplace nationwide, adding 175 new registered members in Q4 2021, bringing the total registered members to approximately 13,100+ at the end of 2021.
Revenues for the fourth quarter of 2021 increased
Gross profit in the fourth quarter of 2021 increased
Operating expenses in the fourth quarter of 2021 were
Net Loss in the fourth quarter of 2021 was (
Adjusted EBITDA, a non-GAAP financial measure, decreased to negative
Fiscal Year Ended December 31, 2021 Summary
Revenues for the 2021 year decreased
Gross profit in fiscal 2021 decreased
Operating expenses in 2021 were
Net Loss in 2021 was (
Adjusted EBITDA for the year ended 2021 was negative (
Looking at our balance sheet, cash and cash equivalents were
Conference Call and Webcast
Management will host a conference call on Monday, March 28, 2022, at 5:00 p.m. Eastern time to discuss TRxADE HEALTH's fourth quarter and fiscal year 2021 financial results. The call will conclude with Q&A from participants. To participate, please use the following information:
Q4 and Fiscal Year 2020 Conference Call and Webcast
Date: Monday, March 28, 2021
Time: 5:00 p.m. Eastern time
U.S. Dial-in: 1-877-425-9470
International Dial-in: 1-201-389-0878
Conference ID: 13727651
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1534472&tp_key=20fddfb1b1
Please dial in at least 10 minutes before the start of the call to ensure timely participation.
A playback of the call will be available through April 28, 2022. To listen, call 1-844-512-2921 within the United States or 1-412-317-6671 when calling internationally and enter replay pin number 13727651. A webcast will also be available for 30 days on the IR section of the TRxADE HEALTH, INC. website or by clicking the webcast link above.
About TRxADE HEALTH, INC.
TRxADE HEALTH (NASDAQ:MEDS) is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S. The Company operates the TRxADE drug procurement marketplace serving a total of 13,100+ members nationwide, fostering price transparency and under the Bonum Health brand, offering patient centric telehealth services. For more information on TRxADE HEALTH, please visit the Company's IR website at investors.trxadegroup.com.
Use of Non-GAAP Financial Information
In addition to our results calculated under generally accepted accounting principles in the United States ("GAAP"), in this earnings release we also present EBITDA and Adjusted EBITDA which are "non-GAAP financial measures" presented as supplemental measures of the Company's performance. They are not presented in accordance with GAAP. EBITDA represents net income before interest, taxes, depreciation and amortization. Adjusted EBITDA is defined as EBITDA before stock-based compensation expense, loss (gain) on inventory investment and loss (gain) on impairment of goodwill. EBITDA and Adjusted EBITDA are presented because we believe they provide additional useful information to investors due to the various noncash items during the period. EBITDA and Adjusted EBITDA are also frequently used by analysts, investors and other interested parties to evaluate companies in our industry. We believe these non-GAAP financial measures are useful to investors both because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and (2) they are used by our institutional investors and the analyst community to help them analyze the health of our business. EBITDA and Adjusted EBITDA have limitations as analytical tools, and you should not consider them in isolation, or as a substitute for analysis of our operating results as reported under GAAP. Some of these limitations are: EBITDA and Adjusted EBITDA do not reflect cash expenditures, future requirements for capital expenditures, or contractual commitments; EBITDA and Adjusted EBITDA do not reflect changes in, or cash requirements for, working capital needs; and EBITDA and Adjusted EBITDA do not reflect the significant interest expense, or the cash requirements necessary to service interest or principal payments, on debt or cash income tax payments. Although depreciation and amortization are noncash charges, the assets being depreciated and amortized will often have to be replaced in the future, and EBITDA and Adjusted EBITDA do not reflect any cash requirements for such replacements. Additionally, other companies in our industry may calculate EBITDA and Adjusted EBITDA differently than TRxADE HEALTH, Inc. does, limiting its usefulness as a comparative measure. EBITDA and Adjusted EBITDA are not recognized in accordance with GAAP, are unaudited, and have limitations as analytical tools, and you should not consider them in isolation, or as substitutes for analysis of the Company's results as reported under GAAP. The Company's presentation of these measures should not be construed as an inference that future results will be unaffected by unusual or nonrecurring items. We compensate for these limitations by providing a reconciliation of each of these non-GAAP measures to the most comparable GAAP measure. We encourage investors and others to review our business, results of operations, and financial information in their entirety, not to rely on any single financial measure, and to view these non-GAAP measures in conjunction with the most directly comparable GAAP financial measure. For more information on these non-GAAP financial measures, please see the section titled "Reconciliation of Net Income attributable to TRxADE HEALTH, INC., to Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA) and Adjusted EBITDA", included at the end of this release.
Forward-Looking Statements
This press release may contain forward-looking statements, including information about management's view of TRxADE's future expectations, plans and prospects, within the meaning of the federal securities laws, including the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. In particular, when used in the preceding discussion, the words "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue," "likely," "will," "would" and variations of these terms and similar expressions, or the negative of these terms or similar expressions are intended to identify forward-looking statements. Any statements made in this news release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of TRxADE, its divisions and concepts to be materially different than those expressed or implied in such statements. These risks include risks relating to agreements with third parties, including Coborn's; the planned benefits, expected users of, and projected revenues of our joint venture with Exchange Health; our operations not being profitable; the commercial viability of new business lines, applications, products and technologies, and the costs of such items; the Company's stock repurchase program; the adoption of the Company's product offerings; claims relating to alleged violations of intellectual property rights of others; our ability to monetize our technological solutions; technical problems with our websites, apps and products; risks relating to implementing our acquisition strategies; challenges to the pharmaceutical supply chain posted by the COVID-19 pandemic and related matters; our ability to manage our growth; negative effects on our operations associated with the opioid pain medication health crisis; regulatory and licensing requirement risks; risks related to changes in the U.S. healthcare environment; the status of our information systems, facilities and distribution networks; risks associated with the operations of our more established competitors; regulatory changes; new competitors which may have more resources than we do; increases in direct to consumer sales of drugs; healthcare fraud; COVID-19, governmental responses thereto, economic downturns and increased inflation and possible recessions caused thereby; changes in laws or regulations relating to our operations; privacy laws; system errors; dependence on current management; our growth strategy; dilution which may be caused by future offerings; our ability to raise funding in the future, as and if needed, and the terms of such funding; increased inflation; and others that are included from time to time in filings made by TRxADE with the Securities and Exchange Commission, including, but not limited to, in the "Risk Factors" sections in its Form 10-Ks and Form 10-Qs and in its Form 8-Ks, which it has filed, and files from time to time, with the U.S. Securities and Exchange Commission (SEC), and more particularly in the Annual Report on Form 10-K filed today with the SEC. These reports are available at www.sec.gov. Other unknown or unpredictable factors also could have material adverse effects on TRxADE's future results and/or could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements. The forward-looking statements included in this press release are made only as of the date hereof. TRxADE cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. We undertake no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.
Investor Relations:
IR@trxade.com
Investors.trxadegroup.com
TRxADE HEALTH, INC.
Consolidated Balance Sheets
December 31, 2021 and 2020
| December 31, 2021 | December 31, 2020 | |||||||
Assets | ||||||||
Current Assets | ||||||||
Cash | $ | 3,122,578 | $ | 5,919,578 | ||||
Accounts Receivable, net | 978,973 | 805,043 | ||||||
Inventory | 56,279 | 1,257,754 | ||||||
Prepaid Assets | 216,414 | 151,248 | ||||||
Other Receivables | - | 1,087,675 | ||||||
Total Current Assets | 4,374,244 | 9,221,298 | ||||||
Property Plant and Equipment, Net | 98,751 | 162,397 | ||||||
Other Assets | ||||||||
Deposits | 60,136 | 21,636 | ||||||
Right of use leased assets | 1,233,033 | 387,371 | ||||||
Total Assets | $ | 5,766,164 | $ | 9,792,702 | ||||
Liabilities and Stockholders' Equity | ||||||||
Current Liabilities | ||||||||
Accounts Payable | $ | 477,028 | $ | 256,829 | ||||
Accrued Liabilities | 270,437 | 219,256 | ||||||
Current Portion - Operating Lease Liabilities | 178,561 | 131,153 | ||||||
Customer Deposits | - | 10,000 | ||||||
Notes Payable - Related Party | - | 225,000 | ||||||
Total Current Liabilities | 926,026 | 842,238 | ||||||
Long Term Liabilities | ||||||||
Operating Lease Liabilities, net of current portion | 1,069,965 | 271,306 | ||||||
Total Liabilities | 1,995,991 | 1,113,544 | ||||||
Stockholders' Equity | ||||||||
Series A Preferred Stock, | - | - | ||||||
Common Stock, | 82 | 81 | ||||||
Additional Paid-in Capital | 20,017,528 | 19,610,631 | ||||||
Retained Deficit | (16,247,437 | ) | (10,931,554 | ) | ||||
Total Stockholders' Equity | 3,770,173 | 8,679,158 | ||||||
Total Liabilities and Stockholders' Equity | $ | 5,766,164 | $ | 9,792,702 | ||||
TRxADE HEALTH, INC.
Consolidated Statements of Operations
Years Ended December 31, 2021 and 2020
| 2021 | 2020 | |||||||
Revenues, net | $ | 9,889,433 | $ | 17,122,520 | ||||
Cost of Sales | 5,143,468 | 11,415,198 | ||||||
Gross Profit | 4,745,965 | 5,707,322 | ||||||
Operating Expenses | ||||||||
Loss on Inventory Investment | 1,226,426 | - | ||||||
Loss on Impairment of Goodwill | - | 725,973 | ||||||
General and Administrative | 8,811,832 | 7,488,011 | ||||||
Total Operating Expenses | 10,038,258 | 8,213,984 | ||||||
Operating Loss | (5,292,293 | ) | (2,506,662 | ) | ||||
Interest Expense | (23,590 | ) | (29,389 | ) | ||||
Net Loss | $ | (5,315,883 | ) | $ | (2,536,051 | ) | ||
Net Loss per Common Share - Basic and Diluted | $ | (0.65 | ) | $ | (0.33 | ) | ||
Weighted average Common Shares Outstanding - Basic and Diluted | 8,136,740 | 7,705,620 | ||||||
TRxADE HEALTH, INC.
Consolidated Statements of Cash Flows
Years ended December 31, 2021 and 2020
| 2021 | 2020 | |||||||
Operating Activities: | ||||||||
Net loss | $ | (5,315,883 | ) | $ | (2,536,051 | ) | ||
Adjustments to reconcile net income (loss) to net cash provided by operating activities: | ||||||||
Depreciation Expense | 7,351 | 5,500 | ||||||
Options Expense | 187,273 | 448,404 | ||||||
Warrant Expense | 21,640 | 56,885 | ||||||
Common Stock Issued for Services | 181,163 | 1,357,759 | ||||||
Bad Debt Expense | 615,657 | 10,539 | ||||||
Loss on Inventory Investment | 143,891 | - | ||||||
Loss on Impairment of Goodwill | - | 725,973 | ||||||
Loss on write-down of Inventory | 376,348 | 1,218,020 | ||||||
Amortization of Right-of-Use Asset | 131,558 | 97,020 | ||||||
Changes in operating assets and liabilities: | ||||||||
Accounts Receivable | (789,587 | ) | (23,532 | ) | ||||
Prepaid Assets and Other Current Assets | (103,666 | ) | (68,796 | ) | ||||
Inventory | 825,127 | (2,419,013 | ) | |||||
Deposits for Inventory Purchases | - | (1,087,675 | ) | |||||
Other Receivables | 1,087,675 | - | ||||||
Lease Liability | (131,153 | ) | (97,033 | ) | ||||
Accounts Payable | 220,199 | (33,190 | ) | |||||
Accrued Liabilities and Other Liabilities | (13,819 | ) | 120,404 | |||||
Customer Deposits | (10,000 | ) | 10,000 | |||||
Net cash used in operating activities | (2,566,226 | ) | (2,214,786 | ) | ||||
Investing Activities: | ||||||||
Purchase of Fixed Assets | (22,596 | ) | (37,505 | ) | ||||
Net cash used in Investing Activities | (22,596 | ) | (37,505 | ) | ||||
Financing Activities: | ||||||||
Repayments of Short-Term Promissory Notes - Related Parties | (225,000 | ) | - | |||||
Payment of Stock Issuance Costs | - | (732,356 | ) | |||||
Proceeds from Exercise of Warrants | 15,001 | 37,606 | ||||||
Proceeds from Exercise of Stock Options | 1,821 | 501 | ||||||
Proceeds from Issuance of Common Stock | - | 5,994,424 | ||||||
Net Cash provided by (used in) financing activities | (208,178 | ) | 5,300,175 | |||||
Net increase (decrease) in Cash | (2,797,000 | ) | 3,047,884 | |||||
Cash at Beginning of the Year | 5,919,578 | 2,871,694 | ||||||
Cash at End of the Year | $ | 3,122,578 | $ | 5,919,578 | ||||
Supplemental Cash Flow Information | ||||||||
Cash Paid for Interest | $ | 28,337 | $ | 29,442 | ||||
Cash Paid for Income Taxes | $ | - | $ | - | ||||
Non-Cash Transactions | ||||||||
Remeasurement of ROU Assets and Lease Liability for Nonrenewal of Lease | $ | - | $ | 273,319 | ||||
Reconciliation of Net Income (Loss) attributable to TRxADE HEALTH, INC., to Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA) and Adjusted EBITDA*
| For the three months ended December 31, | Fiscal Year ended December 31, | ||||||||||||||||
| 2021 | 2020 | 2021 | 2020 | ||||||||||||||
Net loss attributable to TRxADE HEALTH, INC. | $ | (784,340 | ) | $ | (2,312,612 | ) | $ | (5,315,883 | ) | $ | (2,536,051 | ) | |||||
Add (deduct): | |||||||||||||||||
Interest, net | 2,016 | 6,725 | 23,590 | 29,389 | |||||||||||||
Depreciation and amortization | 2,101 | 1,750 | 7,351 | 5.500 | |||||||||||||
EBITDA | (780,223 | ) | (2,303,687 | ) | (5,284,942 | ) | (2,501,162 | ) | |||||||||
Add (deduct): | |||||||||||||||||
Loss on Inventory Investment | - | - | 1,226,426 | - | |||||||||||||
Loss on impairment of Goodwill | - | 725,973 | - | 725,973 | |||||||||||||
Stock-based compensation | (62,782 | ) | 162,877 | 390,076 | 1,863,048 | ||||||||||||
Adjusted EBITDA * | $ | (843,005 | ) | $ | (1,414,837 | ) | $ | (3,668,440 | ) | $ | 87,859 | ||||||
* EBITDA and Adjusted EBITDA are non-GAAP financial measures. These measurements are not recognized in accordance with GAAP and should not be viewed as an alternative to GAAP measures of performance. See also "Use of Non-GAAP Financial Measures", above.
SOURCE: TRxADE HEALTH, Inc.
View source version on accesswire.com:
https://www.accesswire.com/694868/TRxADE-HEALTH-Reports-Year-End-2021-Financial-Results
FAQ
What were TRxADE HEALTH's financial results for Q4 2021?
How did TRxADE HEALTH perform financially in FY 2021?
What is the gross profit for Q4 2021 for TRxADE HEALTH?
What are the future prospects for TRxADE HEALTH?
